Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 12/20 | 0.38 |
| ▸ | FAP | Q12884 | 2/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311754 | 1.00 | DPP4 (0.41) | DPP4DPP7DPP8CYP3A4SMYD3 | |
| SCHEMBL28752306 | 0.83 | DPP4 (0.46) | DPP4DPP7DPP8FAPPREP | |
| SCHEMBL1587326 | 0.82 | CHRNB2 (0.42) | DPP4DPP7DPP8 | |
| SCHEMBL4072047 | 0.80 | ALDH1A1 (0.35) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL27848373 | 0.80 | ALDH1A1 (0.35) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL1098525 | 0.80 | ALDH1A1 (0.35) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL2768507 | 0.79 | DPP4 (0.44) | DPP4DPP7DPP8SMYD3FAP | |
| SCHEMBL14656016 | 0.79 | — | — | |
| SCHEMBL1189333 | 0.79 | DPP4 (0.44) | DPP4DPP7DPP8SMYD3FAP | |
| SCHEMBL26644129 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | DPP4 694/4885DPP7 904/4885DPP8 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.